Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Bensimon
Cn5 - Cost-Effectiveness of Pembrolizumab Versus Standard-Of-Care Chemotherapies for First-Line Treatment of Pd-L1 Positive (≥50%) Metastatic Non-Small Cell Lung Cancer in France
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn178 - Cost-Effectiveness of Pembrolizumab as Second-Line Treatment for Patients With Advanced Urothelial Cancer in France
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pharmacoeconomic Evaluation of PD-L1 Receptor Inhibitors for the Second Line Treatment of Metastatic Non-Small Cell Lung Cancer
Medical Technologies. Assessment and Choice
Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer
Current Oncology
Oncology
Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Network Meta-Analysis
Immunotherapy
Oncology
Allergy
Immunology
Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost Effectiveness of PD-L1-Based Test-And-Treat Strategy With Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
PharmacoEconomics - Open
Health Policy
Pharmacology
Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy for Previously Untreated Metastatic Non-Small Cell Lung Cancer in the USA
BMJ Open
Medicine
P1.16-07 Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients With High PD-L1 Expression in Singapore
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Immunotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
